Prothena Corporation plc Publishes Presentation on Advancements in Life-Saving Therapies for Protein Dysregulation Diseases
Prothena Corporation plc has published a presentation on its advancements in developing therapies for protein dysregulation diseases, including Alzheimer's and Parkinson's. The presentation details their focus on therapeutics that eliminate pathogenic proteins while preserving normal biology, featuring multiple clinical programs, including partnered Phase 2 and a wholly-owned Phase 1 program. Prothena collaborates with Bristol Myers Squibb, Novo Nordisk, and Roche, highlighting the global impact and economic burden of neurodegenerative diseases.
Prothena Corporation plc has released a presentation detailing its ongoing efforts in developing life-saving therapies for diseases related to protein dysregulation, such as Alzheimer's disease, Parkinson's disease, and transthyretin amyloidosis. The presentation highlights the company's focus on therapeutics engineered to eliminate pathogenic proteins while preserving normal biology, utilizing a biology-directed engine for disease-driven antibody engineering. It outlines multiple clinical programs, including three partnered Phase 2 programs and one wholly-owned Phase 1 program. Prothena has established strong collaborations with partners like Bristol Myers Squibb, Novo Nordisk, and Roche. The presentation also emphasizes the global impact of neurodegenerative diseases and the economic burden they pose. You can access the full presentation through the link below.
